Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OSTX
Strong SellHot AirOS Therapies Incorporated · Healthcare · United States · $76M · Avg Vol: $820K/d
15
StockRankGet insider-trade alerts
Q
15
V
25
M
55
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
COMPANY DESCRIPTION
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 26.6M | — |
| EPS | — | -0.14 | -0.17 | -0.59 | -0.98 | — | -1.09 | -0.68 | 0.32 | — |
| Shares | — | 45.5M | 45.5M | 45.5M | 37.1M | -18.5% | 46.5M | — | — | — |
| Debt | 7.1M | 10.3M | 14.6M | — | — | 43.7% | — | — | — | — |
| Equity | — | -17.6M | -24.0M | -3.3M | -6.1M | — | — | — | — | — |
| Op CF | — | -3.8M | -3.0M | -7.3M | -14.2M | — | -18.5M | — | — | — |
| Inv CF | — | 0.2M | 1.1K | 0 | -0.5M | — | — | — | — | — |
| Fin CF | — | 3.7M | 2.9M | 12.8M | 9.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+16.7%
SMA 50SMA 200
Close
$1.82
RSI (14)
68.7
52W High
$2.35
From 52W High
0.8%
SCORE BREAKDOWN
Quality
15
ROIC (ROA)
-232.7%*2.1
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-215.0%0.6
Piotroski
211.9
Int. Cover
-50.0x5.9
D/E Ratio
—N/A
Current Ratio
0.18x0.6
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-2.4x25.0
P/FCF
—N/A
P/B
-7.1x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
55
52W High %
77%64.2
RS 6M
5%71.2
SMA 50/200
1.02x61.1
EPS Rev 4W
-10.2%8.6
EPS Rev 12W
—N/A
EPS Improve
+130%80.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$76M
P/E (Forward)
5.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OSTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OSTX | OS Therapies Incorporated(you) | $76M | 15 | Strong Sell |
| LONA | LeonaBio, Inc. | $75M | 18 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 18 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%